Cancer Treatment-Related Cardiotoxicity


Overview

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prevent recurrence, prolong life and provide cure. However, many of these treatments can cause devastating cardiovascular complications for the patient such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. Developing and understanding optimal prevention, early detection and treatment strategies for cardiotoxicity related to anticancer treatment is a critical aspect of cancer patient care, and may have a significant impact on the overall prognosis and survival of cancer patients. These important clinical events are a significant challenge for both cardiologists and oncologists and will continue to be in the future, particularly due to an increasing aging population of patients with cancer and the introduction of many new targeted cancer therapies.

Efforts to identify individual toxicity risks and prevention strategies support the National Cancer Insitute's (NCI) goal of reducing the burden of cancer diagnoses and treatment outcomes. NCI's vision for the future includes precision medicine that not only provides effective therapy for eradicating disease, but also maintains the function of normal tissues, thus decreasing the burden of cancer throughout the survivorship spectrum.

Return to Top

Funding Opportunities

There are not currently any specific NCI Requests for Applications (RFAs) or Program Announcements (PAs) for cancer treatment-related cardiotoxicity research; however, EGRP encourages investigator-initiated applications on topics related to cardiotoxicity and cancer.

View the full list of EGRP FOAs.

Return to Top

Key Publications

Cancer Treatment-Related Cardiotoxicity Publications
This list provides links to a compilation of scientific publications that may be of interest to researchers studying cardiotoxicities related to cancer treatments.

Return to Top

Workshops, Conferences, and Webinars

Return to Top

Contacts

For general questions about cancer treatment-related cardiotoxicity, contact:

  • Nonniekaye F. Shelburne, C.R.N.P., M.S., A.O.C.N. Program Director, Clinical and Translational Epidemiology Branch

Return to Top